Sanofi-aventis and employees unite for the victims of Haiti

sanofi-aventisIn the face of the unprecedented earthquake that hit the island of Haiti, sanofi-aventis has committed 1 million Euros in financial aid to long-term reconstruction initiatives and the rehabilitation of the population of Haiti.

Since the beginning of this unsurpassed crisis, the teams of sanofi-aventis have been mobilized working with the Authorities and teams on the ground to ensure the release of a first urgent financial aid of 100,000 Euros and considerable donations of medicines and vaccines. The Group will continue to do so.

"We are profoundly affected by the magnitude of the tragedy, which has struck Haiti, and we would like to express our sincere compassion to the families of the victims," declared Christopher A. Viehbacher, Chief Executive Officer, sanofi-aventis. "Solidarity is integral to the DNA of our Group and I consider it our responsibility as a worldwide diversified healthcare leader to respond to the essential health requirements of these victims, in dire need."

Sanofi-aventis has also called on the generosity of its employees worldwide to support the cause. The resulting donations will be matched by the Group. For each donated euro, the Group will donate an additional euro, multiplying by two the available fund.

Employees donations will help support the post-emergency programme driven by six associations, Aide Médicale Internationale, Care, the Red Cross, Handicap International, Médecins du Monde and UNICEF, all of which are specialists experienced in extreme situations, are chosen partners of our Group and are already present in Haiti. These associations will ensure the co-ordination of all implemented actions in the best interest of the people affected.

About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT : SAN) and in New York (NYSE : SNY). For more information, visit: www.sanofi-aventis.us or www.sanofi-aventis.com.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...

Pfizer and Astellas amend clinical research protoc…

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced amendments to the protocols for two registratio...